Summary

Effective adjunctive treatment of acute coronary syndrome with antithrombin therapy is essential to reduce ischemic complications, and researchers continue to compare novel antithrombotic agents with currently available ones in an effort to optimize outcomes. These comparisons require careful evaluation of the benefit-risk balance, with a primary consideration of reduction of ischemic complications weighed against bleeding risk.